美国血液肿瘤专家:萨摩K.哈立德(Samer K.Khale)
好医友 · 2017/09/27
萨摩K.哈立德(Samer K.Khale)博士是美国希望之城国家医学中心 (City Of Hope National Medical Center)的血液肿瘤学专家,并担任血液学与造血干细胞移植部门的临床助理教授。

在线轻松预约,无需出国即可与美国医生“面对面”视频交流,获取权威专业的第二诊疗意见和方案!登录好医友官网查询更多美国医生信息(咨询热线4008860922)


【医生简介】


萨摩K.哈立德(Samer K.Khale)博士是美国希望之城国家医学中心 (City Of Hope National Medical Center)的血液肿瘤学专家,并担任血液学与造血干细胞移植部门的临床助理教授。希望之城国家医学中心是美国国际癌症研究所指定的仅有的48家综合性癌症中心之一,在病人医疗护理、基础与临床研究、科学转化临床受益等领域是业界公认的“领导者”。哈立德博士临床专精于急性髓性白血病、急性淋巴细胞白血病、霍奇金淋巴瘤、非霍奇金淋巴瘤、多发性骨髓瘤等各类血液肿瘤的诊断和治疗,开展了多项临床试验,研究侧重于急性白血病、骨髓造血干细胞移植、移植物抗宿主病(GVHD)、细胞免疫疗法等领域。


【教育背景】

医学教育:毕业于埃及开罗大学医学院(Faculty of Medicine, Cairo University, Egypt),获得医学博士学位;

住院医培训:在纽约布鲁克林医院中心(The Brooklyn Hospital Center, Brooklyn, NY)内科接受住院医师训练,期间担任内科首席住院医师;

专科培训:在鲁克林医院中心(The Brooklyn Hospital Center)血液与肿瘤学部门接受专科临床培训;在希望之城(City of Hope)血液与造血干细胞移植部门完成骨髓移植专科培训。

 

【出版物摘选】

  Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL.(B细胞型非霍奇金淋巴瘤患者自体造血干细胞移植后行CD19CART T细胞疗法获得的中央内存的第一阶段研究)Blood. 2016 Jun 16;127(24):2980-90

  Philadelphia chromosome as a recurrent event among therapy-related acute leukemia.Aldoss I, Stiller T, Song J, AlMalki M, Ali H, Salhotra A, Aribi A, Khaled S, Gaytan P, Murata-Collins J, Palmer J, Snyder D, O'Donnell M, Nakamura R, Stein AS, Forman...; Am. J. Hematol.. 2016-11-10.

  A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hem...Magenau J, Westervelt P, Khaled S, McGuirk J, Hari P, Eapen M, Becker PS, Parkin B, Braun T, Logan B, Wang H, Jagasia M, Rowley SD, Kim DDH, Schechter T, Frey N, Scott...; Bone Marrow Transplant.. 2016-07-18.

  Influence of Absorption, Distribution, Metabolism, and Excretion Genomic Variants on Tacrolimus/Sirolimus Blood Levels and Graft-versus-Host Disease after Allogeneic H...Khaled, S. K.,Palmer, J. M.,Herzog, J.,Stiller, T.,Tsai, N. C.,Senitzer, D.,Liu, X.,Thomas, S. H.,Shayani, S.,Weitzel, J.,Forman, S. J.,Nakamura, R.; Biol. Blood Marrow Transplant.. 2015 Sep 02.

  Mycophenolate mofetil-based salvage as acute GVHD prophylaxis after early discontinuation of tacrolimus and/or sirolimus.Ali H, Palmer J, Eroglu Z, Stiller T, Thomas SH, Khaled S, Shayani S, Parker P, Forman SJ, Nakamura R; Bone Marrow Transplant.. 2015-02-01.

  26 citationsThrombotic Microangiopathy Associated with Sirolimus Level after Allogeneic Hematopoietic Cell Transplantation with Tacrolimus/Sirolimus-Based Graft-versus-Host Diseas...Shayani, S.,Palmer, J.,Stiller, T.,Liu, X.,Thomas, S. H.,Khuu, T.,Parker, P. M.,Khaled, S. K.,Forman, S. J.,Nakamura, R.; Biol Blood Marrow Transplant. 2013 Feb.

  13 citationsA phase II study of sirolimus, tacrolimus and rabbit anti-thymocyte globulin as GVHD prophylaxis after unrelated-donor PBSC transplant.Khaled, S. K.,Palmer, J.,Stiller, T.,Senitzer, D.,Maegawa, R.,Rodriguez, R.,Parker, P. M.,Nademanee, A.,Cai, J. L.,Snyder, D. S.,Karanes, C.,Osorio, E.,Thomas, S. H.,F...; Bone Marrow Transplant. 2013 Feb.

  Allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in adults.Khaled, S. K.,Thomas, S. H.,Forman, S. J.; Curr Opin Oncol. 2012 Jan 12.

 

【临床试验】

· Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL) (JCAR015对成人b细胞急性淋巴细胞白血病(b - all)疗效及安全性的研究)Start of enrollment: 2015 Aug 01Blackman S.C.,Deangelo D.,Ghobadi A.,Khaled S.,Park J.,Wierda W.

· Cellular Immunotherapy After Cyclophosphamide in Treating Patients With High-Risk Acute Lymphoblastic Leukemia(紧接环磷酰胺采用细胞免疫疗法治疗高危急性淋巴细胞白血病患者)Start of enrollment: 2014 Sep 01Khaled, S.

· Phase II Study of Clofarabine and High-Dose Melphalan Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation for Myelodysplasia or Acute Leukemia in Remission(在同种异体造血干细胞移植治疗脊髓发育不良或急性白血病缓解期之前,采用氯法拉滨和高剂量Melphalan的二期研究)Start of enrollment: 2014 Jan 01Khaled, S.

· A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone(Simo二期双级研究:在HMA加入Pracinosta用于那些对HMA无应答或无法维持应答的骨髓增生异常综合征患者)Start of enrollment: 2013 Dec 01Gore, S.D.,Sekeres, M.A.,Khaled, S.,Essell, J.H.,Lyons, R.M.,Heller, B.J.,Faderl, S.H.,Garcia-Manero, G.,Shakil, S.A.,Levy, M.Y.,Yacoub, A.,Patel, P.A.,Dinner, S.N.,Berdeja, J.G.,Maris, M.B.,Mace, J.R.,An...

· A Phase II Open-Label, Single-arm, Two-Stage, Multicenter Trial of Pracinostat in Combination With Azacitidine in Elderly (Age 65 Years or Older) Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)(一项二期、非盲、单臂、双阶段、多中心试验:Pracinostat结合Azacitidine用于治疗65岁及以上的新诊断的急性髓细胞白血病老年患者)Start of enrollment: 2013 Oct 01Medeiros, B.C.,Merchant, A.A.,Garcia-Manero, G.,Khaled, S.,Patel, P.A.,Mims, A.S.,Traer, E.A.,Ferber, A.,Holden, V.R.,Patnaik, M.M.

· Multi-center Single Arm Phase II Study of Myeloablative Allogeneic Stem Cell Transplantation for Non-remission Acute Myeloblastic Leukemia (AML) Using Clofarabine and Busulfan x 4 (CloBu4) Regimen(针对经Clofarabine和 Busulfan治疗无缓解的急性髓细胞白血病患者采用骨髓同种异体干细胞移植的多中心单臂二期试验研究)Start of enrollment: 2011 Nov 01Mineishi, S.

 


  • 2017/10/23
    先天性白内障是由于小孩在母亲体内胎儿发育过程中因为内生性(染色体遗传)或者外生性(胎儿或母体全身疾病)因素影响了晶状体的胚胎发育而发生的混浊。这种疾病较为罕见,它儿童致盲的第二大疾病因素。
  • 2017/10/20
    都说熬夜伤身,很多人却不以为然。最近刷屏的2017年诺贝尔生理学或医学奖关于生物钟的研究表明,熬夜是在与体内的“计时器”作对,会增加患癌风险。
  • 2017/10/18
    以好医友医疗集团为例,基于旗下海量美国优质医疗资源,好医友利用远程医疗技术与中国三甲医院、高端医学中心等共建的院内中美远程会诊平台。
查看更多
发表评论 我在frontend\modules\comment\widgets\views\文件夹下面 test